Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating the Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
NCT06787430Phase 4Not yet recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of nicorandil in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Angiography-derived microcirculatory resistance. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06787430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787430.